Use of agonists or antagonists of the 5-HT7 receptor to treat disorders of the bladder
AssigneeSynaptic Pharmaceutical Corporation
InventorDouglas A. Craig
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT7 receptor antagonist or an antagonist that binds to both 5-HT7 and 5-HT2B receptors. The invention also provides a method of treating urinary retention in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT7 receptor agonist or an agonist that activates both 5-HT7 and 5-HT2B receptors.
Claims18
A method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT7 antagonist which binds to the human 5-HT7 receptor with an affinity at least ten-fold higher than the affinity with which it binds to each of the human 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, and 5-HT6 receptors.
Dependencies are inferred from the claim text.